Yingchao Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yingchao Liu has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Jin Wu
7 shared publicationsJiaqian Wu
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China
4 shared publicationsJieya Chen
4 shared publicationsPei Wu
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China
4 shared publicationsZhouyue Gu
4 shared publicationsFangyuan Zhu
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China
3 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11) , e72381
Plasma IFNL3 for Gastric Cancer Detection and Monitoring in East Asians: A Multiphase Study
Background: Gastric cancer (GC) has a high incidence in East Asia, yet early detection remains limited. Methods: In this multiphase study, 395 participants (96 GC, 72 precancerous lesions, 227 healthy donors) were enrolled. Plasma IFNL3 levels were measured using ELISA. Mendelian randomization was used to assess the causality between IFNL3 and GC. Receiver operating characteristic curves were used to calculate diagnostic efficiency in comparison between IFNL3 and traditional biomarkers (alpha fetoprotein [AFP], carcinoembryonic antigen [CEA], and cancer antigen 19‐9 [CA19‐9]). Results: Bidirectional Mendelian randomization analysis suggested a potential association between plasma IFNL3 and GC in East Asians. In Test phase, plasma IFNL3 demonstrated superior diagnostic performance in differentiating GC from HDs (AUC = 0.901, 95% CI: 0.866–0.935) compared to AFP, CEA, and CA19‐9. IFNL3 levels correlated with disease progression, increasing progressively across clinical stages. IFNL3 mRNA was also higher in cancerous tissues compared to normal and para‐cancerous tissues. In Validation phase, IFNL3 exhibited high diagnostic specificity. In Extension phase, plasma IFNL3 showed distinct diagnostic potential for differentiating chronic non‐atrophic gastritis (CNAG), atrophic intestinal metaplasia (AIM), low‐grade intraepithelial neoplasia (LGIN), and high‐grade intraepithelial neoplasia (HGIN). Conclusions: Plasma IFNL3 levels were increased in gastric cancer and correlated with disease progression. However, its value as a diagnostic biomarker requires validation in larger, stage‐adjusted studies.
- 3 November 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (11) , e72381
Open AccessPlasma IFNL3 for Gastric Cancer Detection and Monitoring in East Asians: A Multiphase Study
Background: Gastric cancer (GC) has a high incidence in East Asia, yet early detection remains limited. Methods: In this multiphase study, 395 participants (96 GC, 72 precancerous lesions, 227 healthy donors) were enrolled. Plasma IFNL3 levels were measured using ELISA. Mendelian randomization was used to assess the causality between IFNL3 and GC. Receiver operating characteristic curves were used to calculate diagnostic efficiency in comparison between IFNL3 and traditional biomarkers (alpha fetoprotein [AFP], carcinoembryonic antigen [CEA], and cancer antigen 19‐9 [CA19‐9]). Results: Bidirectional Mendelian randomization analysis suggested a potential association between plasma IFNL3 and GC in East Asians. In Test phase, plasma IFNL3 demonstrated superior diagnostic performance in differentiating GC from HDs (AUC = 0.901, 95% CI: 0.866–0.935) compared to AFP, CEA, and CA19‐9. IFNL3 levels correlated with disease progression, increasing progressively across clinical stages. IFNL3 mRNA was also higher in cancerous tissues compared to normal and para‐cancerous tissues. In Validation phase, IFNL3 exhibited high diagnostic specificity. In Extension phase, plasma IFNL3 showed distinct diagnostic potential for differentiating chronic non‐atrophic gastritis (CNAG), atrophic intestinal metaplasia (AIM), low‐grade intraepithelial neoplasia (LGIN), and high‐grade intraepithelial neoplasia (HGIN). Conclusions: Plasma IFNL3 levels were increased in gastric cancer and correlated with disease progression. However, its value as a diagnostic biomarker requires validation in larger, stage‐adjusted studies.
- Open Access
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1942618
From mucosal activity to medicinal products: translational evidence for Akkermansia muciniphila extracellular vesicles
Akkermansia muciniphila extracellular vesicles (AKK-EVs) are being investigated as cell-free treatments for intestinal and metabolic disease, but their therapeutic value depends on what they add beyond whole bacteria, purified microbial components, or alternative carriers. This critical narrative review examines 50 publications available up to 19 July 2026, distinguishing vesicle interventions from studies of associated proteins, whole bacteria, and engineered products. Study-level extraction and domain-based appraisal support the comparison of these preparations. The synthesis addresses product identity, causal attribution, exposure, and therapeutic comparison. Native preparations show activity in epithelial and colitis models, while metabolic findings vary with the preparation and experimental setting. For mucosal disease, the therapeutic aim is sustained functional recovery after disease onset. For liver disease, development depends on establishing whether hepatic benefit persists beyond changes in food intake or body weight and whether it results from intestinal activity or delivery to hepatic cells. Engineered products require evidence that the vesicle carrier improves payload delivery or therapeutic index. Whole-cell human trials and observational measurements of EV-associated proteins provide a clinical basis for comparison, but neither establishes the efficacy or safety of administering isolated AKK-EVs to patients. The evidence supports indication-specific preclinical investigation rather than clinical use. Progression towards human studies requires reproducible batches, disease-relevant functional benefit, route-specific repeat-dose safety, and an advantage over a justified active comparator.
- 26 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1942618
Open AccessFrom mucosal activity to medicinal products: translational evidence for Akkermansia muciniphila extracellular vesicles
Akkermansia muciniphila extracellular vesicles (AKK-EVs) are being investigated as cell-free treatments for intestinal and metabolic disease, but their therapeutic value depends on what they add beyond whole bacteria, purified microbial components, or alternative carriers. This critical narrative review examines 50 publications available up to 19 July 2026, distinguishing vesicle interventions from studies of associated proteins, whole bacteria, and engineered products. Study-level extraction and domain-based appraisal support the comparison of these preparations. The synthesis addresses product identity, causal attribution, exposure, and therapeutic comparison. Native preparations show activity in epithelial and colitis models, while metabolic findings vary with the preparation and experimental setting. For mucosal disease, the therapeutic aim is sustained functional recovery after disease onset. For liver disease, development depends on establishing whether hepatic benefit persists beyond changes in food intake or body weight and whether it results from intestinal activity or delivery to hepatic cells. Engineered products require evidence that the vesicle carrier improves payload delivery or therapeutic index. Whole-cell human trials and observational measurements of EV-associated proteins provide a clinical basis for comparison, but neither establishes the efficacy or safety of administering isolated AKK-EVs to patients. The evidence supports indication-specific preclinical investigation rather than clinical use. Progression towards human studies requires reproducible batches, disease-relevant functional benefit, route-specific repeat-dose safety, and an advantage over a justified active comparator.
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Toileting and Continence Difficulty as a Marker of Cognitive Change and Multidimensional Vulnerability in Later Life: A Longitudinal Multi-cohort Study
Background Constipation-related toileting and continence difficulty is usually managed as a bowel or care problem. We tested whether it amplifies cognitive vulnerability during multidimensional deterioration and could indicate when comprehensive geriatric assessment (CGA) should be considered. Methods We analysed CHARLS longitudinally; ELSA, SHARE, HRS, and PPMI supplied complementary evidence. Outcomes were next-wave cognition, high non-cognitive vulnerability, and overall adverse state. Prediction used participant-grouped five-fold cross-validation and 1000 participant-cluster bootstrap resamples. We also examined decision curves, symptom trajectories, functional-overlap sensitivity, attrition, and causal boundaries. Findings Symptom onset preceded lower next-wave memory (adjusted beta -0.084, 95% CI -0.143 to -0.024; p=0.006) and attention/executive scores (-0.103, -0.163 to -0.044; p<0.001). Adding the symptom increased cross-validated AUC for high non-cognitive vulnerability from 0.788 to 0.801 (delta 0.0137, bootstrap 95% CI 0.0101 to 0.0174) and for overall adverse state from 0.764 to 0.775 (0.0112, 0.0080 to 0.0140), but not for low cognition. Associations persisted after excluding ADL/IADL from outcomes. Overall adverse risk was 36.0% with stable absence and 80.8% with persistent symptoms. Interpretation The symptom may be a clinically visible amplifier of cognitive vulnerability within a wider geriatric transition. New or persistent difficulty could prompt cognitive and functional review and consideration of CGA.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessToileting and Continence Difficulty as a Marker of Cognitive Change and Multidimensional Vulnerability in Later Life: A Longitudinal Multi-cohort Study
Background Constipation-related toileting and continence difficulty is usually managed as a bowel or care problem. We tested whether it amplifies cognitive vulnerability during multidimensional deterioration and could indicate when comprehensive geriatric assessment (CGA) should be considered. Methods We analysed CHARLS longitudinally; ELSA, SHARE, HRS, and PPMI supplied complementary evidence. Outcomes were next-wave cognition, high non-cognitive vulnerability, and overall adverse state. Prediction used participant-grouped five-fold cross-validation and 1000 participant-cluster bootstrap resamples. We also examined decision curves, symptom trajectories, functional-overlap sensitivity, attrition, and causal boundaries. Findings Symptom onset preceded lower next-wave memory (adjusted beta -0.084, 95% CI -0.143 to -0.024; p=0.006) and attention/executive scores (-0.103, -0.163 to -0.044; p<0.001). Adding the symptom increased cross-validated AUC for high non-cognitive vulnerability from 0.788 to 0.801 (delta 0.0137, bootstrap 95% CI 0.0101 to 0.0174) and for overall adverse state from 0.764 to 0.775 (0.0112, 0.0080 to 0.0140), but not for low cognition. Associations persisted after excluding ADL/IADL from outcomes. Overall adverse risk was 36.0% with stable absence and 80.8% with persistent symptoms. Interpretation The symptom may be a clinically visible amplifier of cognitive vulnerability within a wider geriatric transition. New or persistent difficulty could prompt cognitive and functional review and consideration of CGA.
- Open Access
- 29 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
RUNX2 drives adenoma-to-carcinoma transition in colon cancer
Colon adenocarcinoma (COAD), the most common subtype of colon cancer, often arises from adenomas. However, the mechanisms driving the adenoma-to-adenocarcinoma transition remain unclear, hindering early intervention and treatment. Single-cell RNA sequencing revealed that CD8 + exhausted T cells (Tex) were significantly enriched in adenoma and carcinoma tissues compared to adjacent normal tissues. Pseudotime analysis and cell-cell communication analysis together revealed a close association between CD8 + Tex cells and epithelial cells (EPCs) during the adenoma-to-adenocarcinoma transition. Ligand-target gene interaction and clustering analysis identified the most critical gene set influenced by CD8 + Tex in the adenoma-to-adenocarcinoma transition. Among these, runt-related transcription factor 2 (RUNX2) was validated as a critical risk factor through the nine-gene risk score model, TCGA data, and qRT-PCR, demonstrating its role in driving this transition. The RUNX2-specific inhibitor CADD522 suppressed RUNX2 expression in vitro and inhibited the adenoma-to-adenocarcinoma transition in the AOM/DSS model. RUNX2 overexpression promoted proliferation, invasion, migration, and adenoma-to-adenocarcinoma transition-related markers in HCT116 and HCT15 cells, while its knockdown reversed these effects. The tumor necrosis factor receptor superfamily member 1 A (TNFRSF1A) agonist tumor necrosis factor-alpha (TNF-α) upregulated RUNX2 expression and partially mitigated the effects of RUNX2 knockdown. Conversely, TNFRSF1A inhibitor Atrosab downregulated RUNX2 expression and partially reversed RUNX2 overexpression-induced adenoma-to-adenocarcinoma transition. Multiplex immunofluorescence confirmed a close spatial association between CD8 + PD-1 + Tex cells and RUNX2 + EPCs. In summary, CD8 + Tex cells may activate RUNX2 in malignant EPCs through TNF-α binding to TNFRSF1A, promoting the adenoma-to-carcinoma transition and contributing to poor prognosis.
- 29 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessRUNX2 drives adenoma-to-carcinoma transition in colon cancer
Colon adenocarcinoma (COAD), the most common subtype of colon cancer, often arises from adenomas. However, the mechanisms driving the adenoma-to-adenocarcinoma transition remain unclear, hindering early intervention and treatment. Single-cell RNA sequencing revealed that CD8 + exhausted T cells (Tex) were significantly enriched in adenoma and carcinoma tissues compared to adjacent normal tissues. Pseudotime analysis and cell-cell communication analysis together revealed a close association between CD8 + Tex cells and epithelial cells (EPCs) during the adenoma-to-adenocarcinoma transition. Ligand-target gene interaction and clustering analysis identified the most critical gene set influenced by CD8 + Tex in the adenoma-to-adenocarcinoma transition. Among these, runt-related transcription factor 2 (RUNX2) was validated as a critical risk factor through the nine-gene risk score model, TCGA data, and qRT-PCR, demonstrating its role in driving this transition. The RUNX2-specific inhibitor CADD522 suppressed RUNX2 expression in vitro and inhibited the adenoma-to-adenocarcinoma transition in the AOM/DSS model. RUNX2 overexpression promoted proliferation, invasion, migration, and adenoma-to-adenocarcinoma transition-related markers in HCT116 and HCT15 cells, while its knockdown reversed these effects. The tumor necrosis factor receptor superfamily member 1 A (TNFRSF1A) agonist tumor necrosis factor-alpha (TNF-α) upregulated RUNX2 expression and partially mitigated the effects of RUNX2 knockdown. Conversely, TNFRSF1A inhibitor Atrosab downregulated RUNX2 expression and partially reversed RUNX2 overexpression-induced adenoma-to-adenocarcinoma transition. Multiplex immunofluorescence confirmed a close spatial association between CD8 + PD-1 + Tex cells and RUNX2 + EPCs. In summary, CD8 + Tex cells may activate RUNX2 in malignant EPCs through TNF-α binding to TNFRSF1A, promoting the adenoma-to-carcinoma transition and contributing to poor prognosis.
- Open Access
- 24 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Combining machine learning and multi-omics analysis to explore the role of CPT1C in colorectal tumor cancer transformation
Colorectal cancer is a common and high-mortality cancer that develops from colorectal adenomas and has a complex process of onset and progression. The CPT1C gene has been found to have a potential oncogenic role in a variety of cancers, but its role in colorectal adenocarcinoma is unclear. The aim of this study was to investigate the expression changes of CPT1C gene in colorectal adenocarcinoma and its clinical significance. Gene expression data from the GEO database were analyzed using machine learning to assess CPT1C differential expression between colorectal adenocarcinoma and adenoma patients. CPT1C was knocked down in HT29 and HCT116 colon cancer cells, and effects on proliferation, migration, and apoptosis were examined via CCK8, scratch, and Annexin V assays. CPT1C expression in human tissues was confirmed by immunohistochemistry. Additionally, the association between CPT1C expression and clinicopathological parameters was analyzed using the TCGA CRC cohort. Machine learning analysis revealed that CPT1C expression was significantly elevated in colorectal adenocarcinoma patients compared to adenoma patients, and high CPT1C expression was associated with poor patient survival. Cellular experiments demonstrated that CPT1C knockdown led to pronounced inhibition of cell proliferation, reduction in migration capabilities, and increased apoptosis in HT29 and HCT116 cells. Immunohistochemical results further confirmed the upregulated expression of CPT1C in colorectal cancer tissues. TCGA cohort analysis revealed that CPT1C expression was significantly associated with disease progression. CPT1C is significantly upregulated in colorectal adenocarcinoma compared with adenoma, and its high expression correlates with disease progression and poor prognosis. Functional assays demonstrate that CPT1C knockdown suppresses proliferation and migration while inducing apoptosis in colorectal cancer cells, highlighting its potential as a therapeutic target.
- 24 April 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessCombining machine learning and multi-omics analysis to explore the role of CPT1C in colorectal tumor cancer transformation
Colorectal cancer is a common and high-mortality cancer that develops from colorectal adenomas and has a complex process of onset and progression. The CPT1C gene has been found to have a potential oncogenic role in a variety of cancers, but its role in colorectal adenocarcinoma is unclear. The aim of this study was to investigate the expression changes of CPT1C gene in colorectal adenocarcinoma and its clinical significance. Gene expression data from the GEO database were analyzed using machine learning to assess CPT1C differential expression between colorectal adenocarcinoma and adenoma patients. CPT1C was knocked down in HT29 and HCT116 colon cancer cells, and effects on proliferation, migration, and apoptosis were examined via CCK8, scratch, and Annexin V assays. CPT1C expression in human tissues was confirmed by immunohistochemistry. Additionally, the association between CPT1C expression and clinicopathological parameters was analyzed using the TCGA CRC cohort. Machine learning analysis revealed that CPT1C expression was significantly elevated in colorectal adenocarcinoma patients compared to adenoma patients, and high CPT1C expression was associated with poor patient survival. Cellular experiments demonstrated that CPT1C knockdown led to pronounced inhibition of cell proliferation, reduction in migration capabilities, and increased apoptosis in HT29 and HCT116 cells. Immunohistochemical results further confirmed the upregulated expression of CPT1C in colorectal cancer tissues. TCGA cohort analysis revealed that CPT1C expression was significantly associated with disease progression. CPT1C is significantly upregulated in colorectal adenocarcinoma compared with adenoma, and its high expression correlates with disease progression and poor prognosis. Functional assays demonstrate that CPT1C knockdown suppresses proliferation and migration while inducing apoptosis in colorectal cancer cells, highlighting its potential as a therapeutic target.
- 18 January 2025
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 48 (8) , 502346
Prevalence and bidirectional association between primary sclerosing cholangitis and Crohn's disease: A systematic review and meta-analysis
- 18 January 2025
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 48 (8) , 502346
Prevalence and bidirectional association between primary sclerosing cholangitis and Crohn's disease: A systematic review and meta-analysis
- Open Access
- 18 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (42) , e40143
Atopic disease and inflammatory bowel disease: A bidirectional Mendelian randomization study
Observational studies have reported associations between atopic diseases, including allergic rhinitis (AR), asthma, atopic dermatitis (AD), and inflammatory bowel disease (IBD), but the causal relationship remains unknown. We utilized pooled data from genome-wide association studies, qualified instrumental variables were screened according to the 3 hypotheses of MR, and bidirectional causality between atopic diseases and IBD was assessed using 2-sample Mendelian randomization analysis (2SMR). The results of our study suggest that AR increased the risk of Crohn disease (CD) (IVW OR = 1.19, 95% CI = 1.02–1.39, P = .026), ulcerative colitis (UC) (IVW OR = 1.14, 95% CI = 1.01–1.29, P = .031) and overall IBD (IVW OR = 1.15, 95% CI = 1.03–1.28, P = .015); Asthma increased the risk of CD (IVW OR = 7.66, 95% CI = 1.58–37.20, P = .012), UC (IVW OR = 3.81, 95% CI = 1.09–13.32, P = .036) and overall IBD (IVW OR = 5.13, 95% CI = 1.48–17.70, P = .010); AD increased the risk of CD (IVW OR = 1.19, 95% CI = 1.02–1.39, P = .023) and overall IBD (IVW OR = 1.14, 95% CI = 1.03–1.28, P = .015) risk. In reverse causality, only CD increased the risk of AR (IVW OR = 1.02, 95% CI = 1.00–1.05, P = .031). This study shows that atopic diseases of AR and asthma are causally related to IBD and its subtypes, and AD is causally related to IBD (which may be attributed to CD). Of the reverse causality, only CD was causally related to AR.
- 18 October 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (42) , e40143
Open AccessAtopic disease and inflammatory bowel disease: A bidirectional Mendelian randomization study
Observational studies have reported associations between atopic diseases, including allergic rhinitis (AR), asthma, atopic dermatitis (AD), and inflammatory bowel disease (IBD), but the causal relationship remains unknown. We utilized pooled data from genome-wide association studies, qualified instrumental variables were screened according to the 3 hypotheses of MR, and bidirectional causality between atopic diseases and IBD was assessed using 2-sample Mendelian randomization analysis (2SMR). The results of our study suggest that AR increased the risk of Crohn disease (CD) (IVW OR = 1.19, 95% CI = 1.02–1.39, P = .026), ulcerative colitis (UC) (IVW OR = 1.14, 95% CI = 1.01–1.29, P = .031) and overall IBD (IVW OR = 1.15, 95% CI = 1.03–1.28, P = .015); Asthma increased the risk of CD (IVW OR = 7.66, 95% CI = 1.58–37.20, P = .012), UC (IVW OR = 3.81, 95% CI = 1.09–13.32, P = .036) and overall IBD (IVW OR = 5.13, 95% CI = 1.48–17.70, P = .010); AD increased the risk of CD (IVW OR = 1.19, 95% CI = 1.02–1.39, P = .023) and overall IBD (IVW OR = 1.14, 95% CI = 1.03–1.28, P = .015) risk. In reverse causality, only CD increased the risk of AR (IVW OR = 1.02, 95% CI = 1.00–1.05, P = .031). This study shows that atopic diseases of AR and asthma are causally related to IBD and its subtypes, and AD is causally related to IBD (which may be attributed to CD). Of the reverse causality, only CD was causally related to AR.
- Open Access
- 27 October 2022
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 16, 3739-3776
Integrated Metabonomics and Network Pharmacology to Reveal the Action Mechanism Effect of Shaoyao Decoction on Ulcerative Colitis
Background: Traditional Chinese medicine (TCM) has the advantage of multi-component and multi-target, which becomes a hot spot in the treatment of numerous diseases. Shaoyao decoction (SYD) is a TCM prescription, which is mainly used to treat damp-heat dysentery clinically, with small side effects and low cost. However, its mechanism remains elusive. The purpose of this study is to explore the mechanism of SYD in the treatment of mice with ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) through metabolomics and network pharmacology, and verify through molecular docking and immunohistochemistry, so as to provide a scientific basis for the role of SYD in the treatment of UC. Materials and Methods: Firstly, DSS-induced UC models were established and then untargeted metabolomics analysis of feces, livers, serum and urine was performed to determine biomarkers and metabolic pathways closely related to the role of SYD. Besides, network pharmacology was applied to screen the active components and UC-related targets, which was verified by molecular docking. Finally, metabonomics and network pharmacology were combined to draw the metabolite-pathway-target network and verified by immunohistochemistry. Results: Metabolomics results showed that a total of 61 differential metabolites were discovered in SYD-treated UC with 3 main metabolic pathways containing glycerophospholipid metabolism, sphingolipid metabolism and biosynthesis of unsaturated fatty acids, as well as 8 core targets involving STAT3, IL1B, IL6, IL2, AKT1, IL4, ICAM1 and CCND1. Molecular docking demonstrated that the first five targets had strong affinity with quercetin, wogonin, kaempferol and baicalein. Combined with metabolomics and network pharmacology, sphingolipid signaling pathway, PI3K/AKT-mTOR signaling pathway and S1P3 pathway were identified as the main pathways. Conclusion: SYD can effectively ameliorate various symptoms and alleviate intestinal mucosal damage and metabolic disorder in DSS induced UC mice. Its effect is mainly related to sphingolipid metabolism, PI3K/AKT-mTOR signaling pathway and S1P3 pathway.
- 27 October 2022
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 16, 3739-3776
Open AccessIntegrated Metabonomics and Network Pharmacology to Reveal the Action Mechanism Effect of Shaoyao Decoction on Ulcerative Colitis
Background: Traditional Chinese medicine (TCM) has the advantage of multi-component and multi-target, which becomes a hot spot in the treatment of numerous diseases. Shaoyao decoction (SYD) is a TCM prescription, which is mainly used to treat damp-heat dysentery clinically, with small side effects and low cost. However, its mechanism remains elusive. The purpose of this study is to explore the mechanism of SYD in the treatment of mice with ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) through metabolomics and network pharmacology, and verify through molecular docking and immunohistochemistry, so as to provide a scientific basis for the role of SYD in the treatment of UC. Materials and Methods: Firstly, DSS-induced UC models were established and then untargeted metabolomics analysis of feces, livers, serum and urine was performed to determine biomarkers and metabolic pathways closely related to the role of SYD. Besides, network pharmacology was applied to screen the active components and UC-related targets, which was verified by molecular docking. Finally, metabonomics and network pharmacology were combined to draw the metabolite-pathway-target network and verified by immunohistochemistry. Results: Metabolomics results showed that a total of 61 differential metabolites were discovered in SYD-treated UC with 3 main metabolic pathways containing glycerophospholipid metabolism, sphingolipid metabolism and biosynthesis of unsaturated fatty acids, as well as 8 core targets involving STAT3, IL1B, IL6, IL2, AKT1, IL4, ICAM1 and CCND1. Molecular docking demonstrated that the first five targets had strong affinity with quercetin, wogonin, kaempferol and baicalein. Combined with metabolomics and network pharmacology, sphingolipid signaling pathway, PI3K/AKT-mTOR signaling pathway and S1P3 pathway were identified as the main pathways. Conclusion: SYD can effectively ameliorate various symptoms and alleviate intestinal mucosal damage and metabolic disorder in DSS induced UC mice. Its effect is mainly related to sphingolipid metabolism, PI3K/AKT-mTOR signaling pathway and S1P3 pathway.
- Open Access
- 1 May 2022
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 16, 1383-1405
Gancao Xiexin Decoction Ameliorates Ulcerative Colitis in Mice via Modulating Gut Microbiota and Metabolites
Purpose: Ulcerative colitis (UC) is a chronic inflammatory bowel disease that starts with mucosal inflammation of the rectum and extends proximally in the colon in a continuous manner over a variable distance. Although it is more common in North America and Western Europe, its incidence is also increasing in Asia. Despite the introduction of several different classes of medications, the treatment options for UC may be insufficiently effective and burdened with significant side effects. In the present study, the therapeutic effects of Gancao Xiexin decoction (GCXX) were investigated on mice with dextran sulfate sodium (DSS)-induced colitis with exploration of the underlying mechanisms. Methods: Colitis was induced in C57BL/6 mice by administering 3% DSS in drinking water for 7 days. GCXX and (or) the standard of care anti-inflammatory drug, mesalazine (5-aminosalicylic acid) were then administered for 7 days. The gut microbiota was characterized by 16S rDNA high-throughput gene sequencing and gut metabolites were detected by untargeted metabolomics. Germ-free mice were subsequently used to determine whether GCXX ameliorated UC principally through modulation of the gut microbiota. Results: GCXX treatment was demonstrated to significantly reduce disease activity index (DAI) scores, prevent colonic shortening, ameliorate colonic tissue damage and reduce the levels of pro-inflammatory cytokines. Furthermore, analysis of the gut microbiota showed that GCXX-treated mice had higher relative quantity of Dubosiella (P< 0.05) and lower relative quantity of Escherichia-Shigella (P< 0.05). Metabolomics analysis indicated that GCXX could reduce the level of linoleic acid (P< 0.05) and regulate its metabolism pathway. Moreover, in germ-free mice, GCXX failed to increase body weight, reduce DAI scores, or alleviate either colonic shortening or colonic damage. Conclusion: The present study demonstrated that GCXX ameliorated DSS-induced colitis principally through modulating the gut microbiota and metabolites. This information should be integrated into the overall mechanisms of GCXX treatment of UC.
- 1 May 2022
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 16, 1383-1405
Open AccessGancao Xiexin Decoction Ameliorates Ulcerative Colitis in Mice via Modulating Gut Microbiota and Metabolites
Purpose: Ulcerative colitis (UC) is a chronic inflammatory bowel disease that starts with mucosal inflammation of the rectum and extends proximally in the colon in a continuous manner over a variable distance. Although it is more common in North America and Western Europe, its incidence is also increasing in Asia. Despite the introduction of several different classes of medications, the treatment options for UC may be insufficiently effective and burdened with significant side effects. In the present study, the therapeutic effects of Gancao Xiexin decoction (GCXX) were investigated on mice with dextran sulfate sodium (DSS)-induced colitis with exploration of the underlying mechanisms. Methods: Colitis was induced in C57BL/6 mice by administering 3% DSS in drinking water for 7 days. GCXX and (or) the standard of care anti-inflammatory drug, mesalazine (5-aminosalicylic acid) were then administered for 7 days. The gut microbiota was characterized by 16S rDNA high-throughput gene sequencing and gut metabolites were detected by untargeted metabolomics. Germ-free mice were subsequently used to determine whether GCXX ameliorated UC principally through modulation of the gut microbiota. Results: GCXX treatment was demonstrated to significantly reduce disease activity index (DAI) scores, prevent colonic shortening, ameliorate colonic tissue damage and reduce the levels of pro-inflammatory cytokines. Furthermore, analysis of the gut microbiota showed that GCXX-treated mice had higher relative quantity of Dubosiella (P< 0.05) and lower relative quantity of Escherichia-Shigella (P< 0.05). Metabolomics analysis indicated that GCXX could reduce the level of linoleic acid (P< 0.05) and regulate its metabolism pathway. Moreover, in germ-free mice, GCXX failed to increase body weight, reduce DAI scores, or alleviate either colonic shortening or colonic damage. Conclusion: The present study demonstrated that GCXX ameliorated DSS-induced colitis principally through modulating the gut microbiota and metabolites. This information should be integrated into the overall mechanisms of GCXX treatment of UC.